Brief: Kiniksa Pharmaceuticals And Huadong Medicine Announce Strategic Collaboration

Kiniksa Pharmaceuticals International

22/02/2022 13:27

Feb 22 (Reuters) - Huadong Medicine Co Ltd  000963.SZ :
    * KINIKSA PHARMACEUTICALS AND HUADONG MEDICINE ANNOUNCE
STRATEGIC
COLLABORATION
    * KINIKSA PHARMACEUTICALS - KINIKSA TO RECEIVE $22 MILLION
UPFRONT; ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL
MILESTONE PAYMENTS AND TIERED ROYALTIES
    * KINIKSA PHARMACEUTICALS LTD - KINIKSA IS ALSO ELIGIBLE TO
RECEIVE TIERED ROYALTIES RANGING FROM LOW-TEENS TO LOW-TWENTIES
ON ANNUAL NET SALES
    * KINIKSA - HUADONG TO OBTAIN EXCLUSIVE RIGHTS,
RESPONSIBILITY FOR
DEVELOPMENT, COMMERCIALIZATION OF ARCALYST, MAVRILIMUMAB IN ASIA
PACIFIC REGION
    * KINIKSA - COLLABORATION INCLUDES RIGHTS TO DEVELOP AND
COMMERCIALIZE ARCALYST AND MAVRILIMUMAB IN ASIA PACIFIC REGION
(EXCLUDING JAPAN)

Source text for Eikon:  ID:nGNX2sZpxK 
Further company coverage:  000963.SZ 

 ((reuters.briefs@thomsonreuters.com;))